IC
KRYS icon

Ikarian Capital’s Krystal Biotech KRYS Stock Holding History

Ikarian Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$17.8M – 141
2024
Q1 		$17.8M Hold
100,000
– – 1.95% 13
2023
Q4 		$12.4M Buy
+100,000
New +$11.1M 1.16% 28
2021
Q4 		– Sell
-282,300
Closed -$14.7M – 218
2021
Q3 		$14.7M Buy
+282,300
New +$16.7M 1.04% 20

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's KRYS Position: Q1 2026 in Review

Ikarian Capital sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 14,814 shares — an estimated $3.65M sold.

Ikarian Capital first reported a position in KRYS in Q3 2025 and held it in 2 quarters. The position peaked at $4.31M in Q3 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Ikarian Capital reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 14,814 Krystal Biotech shares in Q1 2026, an estimated $3.65M.
  • Ikarian Capital first reported a position in Krystal Biotech in Q3 2025 and held it in 2 quarters.
  • Ikarian Capital's Krystal Biotech position peaked at $4.31M in Q3 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.